Kalaris Therapeutics, Inc. Common Stock KLRS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.3M-34.2% | $30.75M-31.7% | $27.45M— | $54.34M— | $49.11M— | ||
| $15.34M+47.3% | $15.4M+130% | $15.04M+8.4% | $13.25M-46.7% | $10.41M-71.4% | ||
| $47.63M-20.0% | $46.15M-10.8% | $42.48M— | $67.59M— | $59.52M— | ||
| -$47.63M+20.0% | -$46.15M+10.8% | -$42.48M+60.3% | -$67.59M+41.8% | -$59.52M+62.6% | ||
| $0-100% | $1.44M-46.6% | $2.75M— | $3.57M— | $4.07M— | ||
| $3.53M+121% | $2.71M+116% | -$12.98M-876% | -$14.06M-19,633% | -$16.43M-899% | ||
| -$44.1M+41.9% | -$43.44M+37.2% | -$55.47M+48.1% | -$81.66M+27.8% | -$75.96M+50.2% | ||
| -$2.15+95.8% | -$4.21+91.8% | -$20.10+73.5% | -$47.62+0.9% | -$51.27-15.8% | ||
| -$47.63M+20.0% | -$46.15M+10.8% | -$42.48M+60.3% | -$67.59M+41.8% | -$59.52M+62.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kalaris Therapeutics, Inc. Common Stock profitable?
- Kalaris Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $44.1M over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's earnings per share?
- Kalaris Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.15.
- Where does Kalaris Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.